tiprankstipranks
Trending News
More News >
Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
:1877

Compare Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. Competitors

Compare
4 Followers

Comparison Results

Name
Price
Market Cap
P/E Ratio
Yearly Gain
Analyst Consensus
Analyst Price Target
Top Analysts' Price Target
Smart Score
Follow
Shanghai Junshi Biosciences Co., Ltd. Class H
HK$21.38
HK$36.44B
-20.84
94.36%
0 Buy
1 Hold
0 Sell
Hold
Zai Lab Ltd
HK$22.18
HK$14.67B
-8.64
-37.18%
6 Buy
2 Hold
0 Sell
Strong Buy
Alphamab Oncology
HK$9.58
HK$8.68B
33.97
175.00%
2 Buy
0 Hold
0 Sell
Moderate Buy
RemeGen Co. Ltd. Class H
HK$84.20
HK$58.04B
-44.61
534.04%
4 Buy
2 Hold
0 Sell
Moderate Buy
Shanghai Henlius Biotech, Inc. Class H
HK$58.60
HK$31.14B
34.99
241.89%
Ascentage Pharma Group International
HK$50.90
HK$17.81B
-12.27
41.68%
1 Buy
0 Hold
0 Sell
Moderate Buy

Performance Comparison

Ticker
Company Name
Price
Change
% Change
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
21.38
10.78
101.70%
HK:9688
Zai Lab Ltd
13.13
-7.72
-37.03%
HK:9966
Alphamab Oncology
8.91
5.58
167.57%
HK:9995
RemeGen Co. Ltd. Class H
84.20
70.60
519.12%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
57.30
40.32
237.46%
HK:6855
Ascentage Pharma Group International
48.10
12.40
34.73%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts